Serum Institute of India to Produce Ebola Vaccine Doses for Clinical Trials
Serum Institute of India will manufacture clinical trial doses of an experimental Ebola vaccine from Oxford University, backed by up to $8.6 million in funding from CEPI. The vaccine uses the same ChAdOx1 platform as the Oxford-AstraZeneca Covid-19 vaccine, aiming for rapid development and affordable access for affected nations in Africa.






